It is used to ease pain. It may be given to you for other reasons also.
Pentazocine is an opioid (narcotic) analgesic. It works in the brain and nervous system to decrease pain. It produces analgesia by an agonistic effect at the kappa receptor. It weakly antagonizes effects of opiates at μ-receptor.
Onset: IM/subcutaneous is 15 to 20 min; IV is 2 to 3 min.
Distribution: Moderate protein binding.
Metabolism: Hepatic.
Elimination: Excreted primarily by the kidney. Half-life is 2 to 3 h.
ORAL Moderate to severe pain: Adult: 50-100 mg every 3-4 hrs; max 600 mg daily. Child: 6-12 yr: As hydrochloride: 25 mg every 3-4 hr. PARENTERAL Moderate to severe pain: Adult: 30-60 mg SC, IM or IV lnj given every 3-4 hr. Child: >1 yr: up to 1 mg/kg SC, IM; up to 500 mcg/ kg IV every 3-4 hr. RECTAL Moderate to severe pain: Adult: 50 mg supp up to 4 times daily. Child: Not recommended.
Drinking of alcohol should be avoided. Dangerous side effects or death can occur when alcohol is combined with pentazocine. Using this medicine with other drugs that make sleepy or slow breathing can worsen these effects. Dizziness or severe drowsiness can cause falls or other accidents. Other drugs may interact with pentazocine, including prescription and over-the-counter medicines, vitamins, and herbal products.
Head injury; narcotic dependence; resp depression; raised intracranial pressure; Ml; heart failure; arterial or pulmonary hypertension; porphyria: pregnancy (prolonged use or high doses at term). May precipitate withdrawal In narcotic addicts. Impaired respiratory, renal & hepatic function; morbidly obese patients; thyroid dysfunction: prostatic hyperplasia or urinary stricture; biliary tract impairment; adrenal insufficiency (including Addison’s disease); abdominal conditions. Elderly or debilitated patients; seizure-prone patients; child & infants (safety & efficacy not established in <1 yr); lactation. May impair ability to drive or operate machinery. Administer IM rather than SC (when frequent inj are needed) & inj sites should be varied.
Physical dependence; sedation, dizziness, euphoria, lightheadedness, alterations of mood; resp depression; visual hallucinations, disorientation, confusion; hypertension, tachycardia, circulatory depression; shock; hypotension; nausea, vomiting, constipation; seizures, diaphoresis; rash; blood dyscrasias; local tissue damages (SC), muscle fibrosis (IM). Respiratory depression, hypotension, circulatory failure, deepening coma, convulsions.
Available data in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage; based on animal data, a potential risk to the fetus cannot be ruled out. This drug has been detected in human milk; newborn infants appear to be particularly sensitive to the effects of even small doses. Once a mother's milk comes in, it is best to provide pain control with nonnarcotic analgesics. The developmental and health benefits of breastfeeding should be considered along with the mother's need for this drug and any potential adverse effects on the breastfed infant or underlying maternal condition. Withdrawal symptoms may occur in breastfed infants when maternal administration of an opioid analgesic is stopped or when breastfeeding is stopped.
Manifestations: Clinical experience with Pentazocine overdosage has been insufficient to define the signs of this condition.
Treatment: Oxygen, intravenous fluids, vasopressors, and other supportive measures should be employed as indicated. Assisted or controlled ventilation should also be considered. For respiratory depression due to overdose or unusual sensitivity to Pentazocine, parenteral naloxone is a specific and effective antagonist.
Keep away from light and store below 25°C. Do not freeze. Keep out of reach of children.
.png&w=384&q=75)